Trial · NCT02406586
Free Fatty Acids-Induced Hypertension in Obese Subjects (Aim #2)
NCT02406586, Not applicable, Completed, Emory University; results first posted 2015-05-28
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Free Fatty Acids-Induced Hypertension in Obese Subjects (Aim #2). Trials, record NCT02406586. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02406586
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Free Fatty Acids-Induced Hypertension in Obese Subjects (Aim #2)
- NCT number
- NCT02406586
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 36 participants, actual
- Lead sponsor
- Emory University
- Conditions
- Hypertension, Diabetes
- Interventions
- Salsalate, Carvedilol, Placebo, Intralipid 20%
- First posted
- 2015-04-02
- Last updated
- 2019-01-08
- Results first posted
- 2015-05-28
Source ClinicalTrials.gov
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Systolic Blood Pressure. | Pre-dose (Baseline), within 4 hours at Baseline visit | Systolic blood pressure is the amount of pressure the heart generates when pumping blood through the arteries to the body. Current guidelines identify normal systolic blood pressure as lower than 120 mmHg. Blood pressure was measured in triplicate with a manual cuff prior to and every 4 hours during the 24-hour infusion with subjects in supine position. Change is the difference in systolic blood pressure at the baseline visit from pre-dosing with Intralipid to 4 hours during Intralipid infusion. |
| Primary | Change in Systolic Blood Pressure | Pre-dose (Baseline), within 8 hours at Baseline visit | Systolic blood pressure is the amount of pressure the heart generates when pumping blood through the arteries to the body. Current guidelines identify normal systolic blood pressure as lower than 120 mmHg. Blood pressure was measured in triplicate with a manual cuff prior to and every 4 hours during the 24-hour infusion with subjects in supine position. from Change is the difference in systolic blood pressure at the baseline visit from pre-dosing with Intralipid to 8 hours during Intralipid. |
| Primary | Change in Systolic Blood Pressure | Pre-dose (Baseline), within 12 hours at Baseline visit | Systolic blood pressure is the amount of pressure the heart generates when pumping blood through the arteries to the body. Current guidelines identify normal systolic blood pressure as lower than 120 mmHg. Blood pressure was measured in triplicate with a manual cuff prior to and every 4 hours during the 24-hour infusion with subjects in supine position. Change is the difference in systolic blood pressure at the baseline visit from pre-dosing with Intralipid to 12 hours during Intralipid infusion. |
| Primary | Change in Systolic Blood Pressure | Pre-dose (Baseline), within 16 hours at Baseline visit | Systolic blood pressure is the amount of pressure the heart generates when pumping blood through the arteries to the body. Current guidelines identify normal systolic blood pressure as lower than 120 mmHg. Blood pressure was measured in triplicate with a manual cuff prior to and every 4 hours during the 24-hour infusion with subjects in supine position. Change is the difference in systolic blood pressure at the baseline visit from pre-dosing with Intralipid to 16 hours during Intralipid infusion. |
| Primary | Change in Systolic Blood Pressure | Pre-dose (Baseline), within 20 hours at Baseline visit | Systolic blood pressure is the amount of pressure the heart generates when pumping blood through the arteries to the body. Current guidelines identify normal systolic blood pressure as lower than 120 mmHg. Blood pressure was measured in triplicate with a manual cuff prior to and every 4 hours during the 24-hour infusion with subjects in supine position. Change is the difference in systolic blood pressure at the baseline visit from pre-dosing with Intralipid to 20 hours during Intralipid infusion. |
| Primary | Change in Systolic Blood Pressure | Pre-dose (Baseline), within 24 hours at Baseline visit | Systolic blood pressure is the amount of pressure the heart generates when pumping blood through the arteries to the body. Current guidelines identify normal systolic blood pressure as lower than 120 mmHg. Blood pressure was measured in triplicate with a manual cuff prior to and every 4 hours during the 24-hour infusion with subjects in supine position. Change is the difference in systolic blood pressure at the baseline visit from pre-dosing with Intralipid to 24 hours during Intralipid infusion. |
| Primary | Change in Systolic Blood Pressure | Pre-dose (Week 6), within 4 hours at Week 6 visit | Systolic blood pressure is the amount of pressure the heart generates when pumping blood through the arteries to the body. Current guidelines identify normal systolic blood pressure as lower than 120 mmHg. Blood pressure was measured in triplicate with a manual cuff prior to and every 4 hours during the 24-hour infusion with subjects in supine position. Change is the difference in systolic blood pressure at Week 6 from pre-dosing with Intralipid to 4 hours during Intralipid infusion. |
| Primary | Change in Systolic Blood Pressure | Pre-dose (Week 6), within 8 hours at Week 6 visit | Systolic blood pressure is the amount of pressure the heart generates when pumping blood through the arteries to the body. Current guidelines identify normal systolic blood pressure as lower than 120 mmHg. Blood pressure was measured in triplicate with a manual cuff prior to and every 4 hours during the 24-hour infusion with subjects in supine position. Change is the difference in systolic blood pressure from at Week 6 from pre-dosing with Intralipid to 8 hours during Intralipid infusion. |
| Primary | Change in Systolic Blood Pressure | Pre-dose (Week 6), within 12 hours at Week 6 visit | Systolic blood pressure is the amount of pressure the heart generates when pumping blood through the arteries to the body. Current guidelines identify normal systolic blood pressure as lower than 120 mmHg. Blood pressure was measured in triplicate with a manual cuff prior to and every 4 hours during the 24-hour infusion with subjects in supine position. Change is the difference in systolic blood pressure at Week 6 from pre-dosing with Intralipid to 12 hours during Intralipid infusion. |
| Primary | Change in Systolic Blood Pressure | Pre-dose (Week 6), within 16 hours at Week 6 visit | Systolic blood pressure is the amount of pressure the heart generates when pumping blood through the arteries to the body. Current guidelines identify normal systolic blood pressure as lower than 120 mmHg. Blood pressure was measured in triplicate with a manual cuff prior to and every 4 hours during the 24-hour infusion with subjects in supine position. Change is the difference in systolic blood pressure at Week 6 from pre-dosing with Intralipid to 16 hours during Intralipid infusion. |
1 to 10 of 23Source ClinicalTrials.gov
See all 23 registered outcomesOutcomes23
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Systolic Blood Pressure. | Pre-dose (Baseline), within 4 hours at Baseline visit | One subject in the salsalate arm withdrew from the study was not included in the baseline analysis population. | mmHg | MEAN |
| PRIMARY | Change in Systolic Blood Pressure | Pre-dose (Baseline), within 8 hours at Baseline visit | One subject in the salsalate arm withdrew from the study was not included in the baseline analysis population. | mmHg | MEAN |
| PRIMARY | Change in Systolic Blood Pressure | Pre-dose (Baseline), within 12 hours at Baseline visit | One subject in the salsalate arm withdrew from the study was not included in the baseline analysis population. | mmHg | MEAN |
| PRIMARY | Change in Systolic Blood Pressure | Pre-dose (Baseline), within 16 hours at Baseline visit | One subject in the salsalate arm withdrew from the study was not included in the baseline analysis population. | mmHg | MEAN |
| PRIMARY | Change in Systolic Blood Pressure | Pre-dose (Baseline), within 20 hours at Baseline visit | One subject in the salsalate arm withdrew from the study was not included in the baseline analysis population. | mmHg | MEAN |
| PRIMARY | Change in Systolic Blood Pressure | Pre-dose (Baseline), within 24 hours at Baseline visit | One subject in the salsalate arm withdrew from the study was not included in the baseline analysis population. | mmHg | MEAN |
| PRIMARY | Change in Systolic Blood Pressure | Pre-dose (Week 6), within 4 hours at Week 6 visit | 7 subjects withdrew from the study prior to the Week 6 visit. Data was also not collected for one additional subject. | mmHg | MEAN |
| PRIMARY | Change in Systolic Blood Pressure | Pre-dose (Week 6), within 8 hours at Week 6 visit | 7 subjects withdrew from the study prior to the Week 6 visit. Data was also not collected for one additional subject. | mmHg | MEAN |
| PRIMARY | Change in Systolic Blood Pressure | Pre-dose (Week 6), within 12 hours at Week 6 visit | 7 subjects withdrew from the study prior to the Week 6 visit. Data was also not collected for one additional subject. | mmHg | MEAN |
| PRIMARY | Change in Systolic Blood Pressure | Pre-dose (Week 6), within 16 hours at Week 6 visit | 7 subjects withdrew from the study prior to the Week 6 visit. Data was also not collected for one additional subject. | mmHg | MEAN |
1 to 10 of 23Source ClinicalTrials.gov
See all 23 outcomesResults by group60
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Systolic Blood Pressure. | Salsalate | 15.37 | Standard Deviation 9.15 | mmHg | |
| Change in Systolic Blood Pressure. | Carvedilol | 10.04 | Standard Deviation 8.72 | mmHg | |
| Change in Systolic Blood Pressure. | Placebo | 10.25 | Standard Deviation 12.83 | mmHg | |
| Change in Systolic Blood Pressure | Salsalate | 13.02 | Standard Deviation 16.42 | mmHg | |
| Change in Systolic Blood Pressure | Carvedilol | 2.03 | Standard Deviation 11.27 | mmHg | |
| Change in Systolic Blood Pressure | Placebo | 5.47 | Standard Deviation 16.81 | mmHg | |
| Change in Systolic Blood Pressure | Salsalate | 20.55 | Standard Deviation 10.06 | mmHg | |
| Change in Systolic Blood Pressure | Carvedilol | 1.74 | Standard Deviation 10.59 | mmHg | |
| Change in Systolic Blood Pressure | Placebo | 5.25 | Standard Deviation 15.64 | mmHg | |
| Change in Systolic Blood Pressure | Salsalate | 15.78 | Standard Deviation 13.12 | mmHg |
1 to 10 of 60Source ClinicalTrials.gov
See all 60 results by groupParticipant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Salsalate | 12 | |
| Overall Study | STARTED | Carvedilol | 12 | |
| Overall Study | STARTED | Placebo | 12 | |
| Overall Study | COMPLETED | Salsalate | 11 | |
| Overall Study | COMPLETED | Carvedilol | 8 | |
| Overall Study | COMPLETED | Placebo | 10 | |
| Overall Study | NOT COMPLETED | Salsalate | 1 | |
| Overall Study | NOT COMPLETED | Carvedilol | 4 | |
| Overall Study | NOT COMPLETED | Placebo | 2 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Salsalate | ||
| Total, all-cause mortality | Carvedilol | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Salsalate | 0 | 12 |
| Total, other adverse events | Carvedilol | 0 | 12 |
| Total, other adverse events | Placebo | 0 | 12 |
| Total, serious adverse events | Salsalate | 0 | 12 |
| Total, serious adverse events | Carvedilol | 0 | 12 |
| Total, serious adverse events | Placebo | 0 | 12 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02406586
GET https://conductscience.org/api/trials/v1/NCT02406586/registered?page=2